Alumis Inc. reports results for the quarter ended June 30 - Earnings Summary
Alumis Inc. reports results for the quarter ended June 30 - Earnings Summary
Alumis Inc. ALMS.OQ reported a quarterly adjusted loss of 79 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.68. The mean expectation of ten analysts for the quarter was for a loss of 73 cents per share. Wall Street expected results to range from -83 cents to -55 cents per share.
Revenue fell 37.7% to $1.66 million from a year ago; analysts expected $3.47 million.
Alumis Inc.'s reported EPS for the quarter was a loss of $1.11.
The company reported a quarterly loss of $142.22 million.
Alumis Inc. shares had fallen by 9.2% this quarter and gained 161.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 1.9% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Alumis Inc. is $39.00, about 34.5% above its last closing price of $25.55
This summary was machine generated from LSEG data August 13 at 08:57 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.73 | -0.79 | Missed |
Mar. 31 2026 | -0.76 | -0.74 | Beat |
Dec. 31 2025 | -0.98 | -0.94 | Beat |
Sep. 30 2025 | -0.92 | -1.06 | Missed |
Recent news on Alumis
See all newsBrief: Alumis Says Envudeucitinib Improves Psoriasis Symptoms in Phase 3 Data
U.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Alumis set for worst day after lupus drug misses main goal in mid-stage trial
Alumis eyes late-stage lupus study despite trial miss (updated)
Alumis tumbles after lupus drug misses main goal in mid-stage trial